Marielle Zoetmulder1,2,3, Miki Nikolic4, Heidi Biernat1, Lise Korbo1, Lars Friberg5, Poul Jennum2,3. 1. Department of Neurology, Bispebjerg Hospital, Copenhagen, Denmark. 2. Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Glostrup Hospital, Copenhagen, Denmark. 3. Center for Healthy Aging, University of Copenhagen, Denmark. 4. Department of Clinical Neurophysiology, Glostrup Hospital, Copenhagen, Denmark. 5. Department of Clinical Physiology and Nuclear Medicine, Bispebjerg University Hospital, Copenhagen, Denmark.
Abstract
STUDY OBJECTIVES: Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by impaired motor inhibition during REM sleep, and dream-enacting behavior. RBD is especially associated with α-synucleinopathies, such as Parkinson disease (PD). Follow-up studies have shown that patients with idiopathic RBD (iRBD) have an increased risk of developing an α-synucleinopathy in later life. Although abundant studies have shown that degeneration of the nigrostriatal dopaminergic system is associated with daytime motor function in Parkinson disease, only few studies have investigated the relation between this system and electromyographic (EMG) activity during sleep. The objective of this study was to investigate the relationship between the nigrostriatal dopamine system and muscle activity during sleep in iRBD and PD. METHODS: 10 iRBD patients, 10 PD patients with PD, 10 PD patients without RBD, and 10 healthy controls were included and assessed with (123)I-N-omega-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane ((123)I-FP-CIT) Single-photon emission computed tomography (SPECT) scanning ((123)I-FP-CIT SPECT), neurological examination, and polysomnography. RESULTS: iRBD patients and PD patients with RBD had increased EMG-activity compared to healthy controls. (123)I-FP-CIT uptake in the putamen-region was highest in controls, followed by iRBD patients, and lowest in PD patients. In iRBD patients, EMG-activity in the mentalis muscle was correlated to (123)I-FP-CIT uptake in the putamen. In PD patients, EMG-activity was correlated to anti-Parkinson medication. CONCLUSIONS: Our results support the hypothesis that increased EMG-activity during REM sleep is at least partly linked to the nigrostriatal dopamine system in iRBD, and with dopamine function in PD.
STUDY OBJECTIVES:Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by impaired motor inhibition during REM sleep, and dream-enacting behavior. RBD is especially associated with α-synucleinopathies, such as Parkinson disease (PD). Follow-up studies have shown that patients with idiopathic RBD (iRBD) have an increased risk of developing an α-synucleinopathy in later life. Although abundant studies have shown that degeneration of the nigrostriatal dopaminergic system is associated with daytime motor function in Parkinson disease, only few studies have investigated the relation between this system and electromyographic (EMG) activity during sleep. The objective of this study was to investigate the relationship between the nigrostriatal dopamine system and muscle activity during sleep in iRBD and PD. METHODS: 10 iRBD patients, 10 PDpatients with PD, 10 PDpatients without RBD, and 10 healthy controls were included and assessed with (123)I-N-omega-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane ((123)I-FP-CIT) Single-photon emission computed tomography (SPECT) scanning ((123)I-FP-CIT SPECT), neurological examination, and polysomnography. RESULTS: iRBD patients and PDpatients with RBD had increased EMG-activity compared to healthy controls. (123)I-FP-CIT uptake in the putamen-region was highest in controls, followed by iRBD patients, and lowest in PDpatients. In iRBD patients, EMG-activity in the mentalis muscle was correlated to (123)I-FP-CIT uptake in the putamen. In PDpatients, EMG-activity was correlated to anti-Parkinson medication. CONCLUSIONS: Our results support the hypothesis that increased EMG-activity during REM sleep is at least partly linked to the nigrostriatal dopamine system in iRBD, and with dopamine function in PD.
Authors: H Almirall; I Pigarev; M D de la Calzada; M Pigareva; M T Herrero; T Sagales Journal: J Neural Transm (Vienna) Date: 1999 Impact factor: 3.575
Authors: A Lokkegaard; L M Werdelin; L Regeur; M Karlsborg; S R Jensen; E Brødsgaard; F F Madsen; M N Lonsdale; L Friberg Journal: Eur J Nucl Med Mol Imaging Date: 2006-11-10 Impact factor: 9.236
Authors: Ariel B Neikrug; Julie A Avanzino; Lianqi Liu; Jeanne E Maglione; Loki Natarajan; Jody Corey-Bloom; Barton W Palmer; Jose S Loredo; Sonia Ancoli-Israel Journal: Sleep Med Date: 2014-05-10 Impact factor: 3.492
Authors: Ilonka Eisensehr; Reiner Linke; Klaus Tatsch; Bita Kharraz; Josef F Gildehaus; Christian T Wetter; Claudia Trenkwalder; Johannes Schwarz; Soheyl Noachtar Journal: Sleep Date: 2003-08-01 Impact factor: 5.849
Authors: Alex Iranzo; Ana Fernández-Arcos; Eduard Tolosa; Mónica Serradell; José Luis Molinuevo; Francesc Valldeoriola; Ellen Gelpi; Isabel Vilaseca; Raquel Sánchez-Valle; Albert Lladó; Carles Gaig; Joan Santamaría Journal: PLoS One Date: 2014-02-26 Impact factor: 3.240
Authors: Rémi Patriat; Pramod K Pisharady; Sommer Amundsen-Huffmaster; Maria Linn-Evans; Michael Howell; Jae Woo Chung; Matthew N Petrucci; Aleksandar Videnovic; Erin Holker; Joshua De Kam; Paul Tuite; Christophe Lenglet; Noam Harel; Colum D MacKinnon Journal: Brain Commun Date: 2022-02-09
Authors: Petr Dušek; Veronika Lorenzo Y Losada Ibarburu; Ondrej Bezdicek; Irene Dall'antonia; Simona Dostálová; Petra Kovalská; Radim Krupička; Jiří Nepožitek; Tomáš Nikolai; Michal Novotný; Pavla Peřinová; Jan Rusz; Tereza Serranová; Tereza Tykalová; Olga Ulmanová; Zuzana Mecková; Václav Ptáčník; Jiří Trnka; David Zogala; Evžen Růžička; Karel Šonka Journal: Sci Rep Date: 2019-10-29 Impact factor: 4.379